Aujourd’hui pourrait être la journée que je prend position…sa fait 1mois j’attend mais je pense qu’avec les bid déjà a 0.57$ avant que le stock ouvre et l’annonce d’un Q bientôt la panic va arrêter et le Highest low devrait être proche de la réalité…mais le marcher peut être traite desfois
Patient Home talks revenue, omits Q3 P&L from NR
2015-08-31 09:14 ET - News Release
Mr. Michael Dalsin reports
PATIENT HOME MONITORING ANNOUNCES ANOTHER RECORD QUARTER OF REVENUE AND PROFIT, REPORTS 194% ANNUALIZED QUARTER-OVER-QUARTER INCREASE IN REVENUE GROWTH
Patient Home Monitoring Corp. has released its financial results for the third quarter of fiscal 2015, ending in June.
Third quarter 2015 highlights
Completed more than $167-million in transactions for the quarter;
Completed $67,275,000 equity financing, building the balance sheet for further acquisitions and organic growth;
Closed a $100,175,545 acquisition of Sleep Management, a company with annualized revenues of $42.5-million, and earnings before interest, taxes, depreciation and amortization margins in excess of 30 per cent;
Increased annualized run-rate revenues to $116-million in June compared with $62,148,000 in March;
Appointed Casey Hoyt as chief executive officer.
Revenue for the quarter rose to $19,354,728, a 48-per-cent increase from the previous quarter and a 255-per-cent increase year over year.
Revenues included only one month of Sleep Management.
Net income before stock-based compensation, transactional and non-recurring costs rose to $3,452,620, a 113-per-cent increase from the previous quarter and a 285-per-cent increase from the same quarter last year.
Adjusted earnings before interest, taxes, depreciation and amortization before transactional and non-recurring cost rose to $4,600,591, a 61-per-cent increase from the previous quarter.
PHM is rolling up a large and fragmented market of small, profitable businesses providing health care products and services to chronically ill patients. The companies are acquired for their technical and market expertise in certain product and service lines, as well as their patient databases. Once acquired, PHM works to offer these newly acquired services to its entire patient base, thereby increasing revenue per patient, and achieving organic postacquisition revenue growth and profits.
“This was truly a transformational quarter for PHM,” said Casey Hoyt, chief executive officer of PHM. "PHM’s vision and goals have never changed, we’re only adding to our arsenal. Not only will we continue to make accretive acquisitions that will benefit our shareholders, we will continue to cross-sell to increase revenues postacquisition. In addition to that, PHM will benefit from our organic growth strategy. We feel our organic growth platform will increase revenues in PHM’s existing businesses. This approach resulted in Sleep Management’s revenues growing 100 per cent year over year over the last three years. It’s a proven model that works and it should have an impact on PHM’s bottom line going forward. We have made investments since closing in order to increase organic growth that will have a positive financial impact as soon as the upcoming quarter. This opportunity is the key reason why Mike and I decided to take take the helm of PHM and lead the company to the next level.
“There is tremendous potential in this quarter-trillion-dollar market. I believe our competitive advantage in this fast-growing market will provide opportunities for significant revenue and profit growth over the coming quarters, and that we have really just begun in terms of building PHM to the vision the management team and board share.”
“This is our ninth consecutive quarter of record revenues and profits,” said Michael Dalsin, non-executive chairman of PHM. “And this quarter is certainly the most crucial quarter PHM has ever had. By raising $67-million and closing a $100-million deal, all in the same quarter, we have moved PHM into the next phase of its life cycle. As part of this transformation, we continue to work on finishing the process for uplisting onto a U.S. exchange and are currently finalizing our process for a senior listing in Canada.”
L’action est en remontée depuis la semaine passée!
Je ré-embarque ici à 0.55$
Pour ceux qui suivent le titre voici un lien pour un entrevue avec Casey Hoyt et Edward Brann:
Avec les récents déboires, je crois à une belle occasion d’achat comme plusieurs autres microcaps présentement.
Patient Home Monitoring is moving higher finally after losing 80 percent of its value since mis-communication by management on the sale of a large insider block. That move prompted a ‘revenge’ mentality on the part of institutions who had, just prior to the insider sale, participated in a $57 million bought deal private placement. Adding to the anger felt by investors was the fact the company had also launched a Normal Course Issuer Bid to buy back up to ~14 million shares.
The insiders, Michael Dalsin and Roger Greene, subsequently resigned from their leadership roles, and put new management in place. The fact that the sale of shares was to position Dalsin and Greene in a new Healthcare fund was lost on the investment community, and that’s the basis of the ‘miscommunication’. There was never any fundamental component of PHM’s business that was in question, except possibly hubris on Dalsin’s part in predicting a $200 million 2015 exit run rate. That number is looking more like $155 million. But with an adjusted EBITDA margin of between 23 and 28 percent, or $0.10 per share on the low end. The company is on the way to becoming a serious money maker and consolidator in the space.
Patient Home Monitoring Posts Record Audited Year-end Financials; Releases Record First Quarter Revenue and Profit Figures
Patient Home Monitoring (PHM) (TSX VENTURE:PHM), a profitable company focused on the annuity-based healthcare services market in the US announced that it posted Audited financials for the year ended September 30, 2015. Along with the full year results, PHM released revenue and profit figures for the quarter ending December 31, 2015.
PHM is offering an ever-larger suite of products and services to an increased geographic footprint in the US. While investing in enrollment growth for all of its existing products and services, PHM’s mission in the market has always been to offer newly reimbursed and high demand services and products to patients. These cutting edge products often offer higher margins and limited competition.
Fiscal First Quarter (Ended December 31, 2015)
Revenues are estimated to exceed $40,000,000 for the quarter, an increase of more than 293% from the same quarter a year ago and an increase of 36% from the previous quarter.
Adjusted EBITDA(1) is currently estimated to be approximately $8,000,000 for the quarter, an increase of more than 236% from the same quarter a year ago and an increase of more than 123% from the previous quarter.
Full results will be posted on SEDAR around the end of January 2016. PHM’s management will hold an interactive earnings call to review the first quarter and full year financials in early February 2016.
Audited Full Year (October 1, 2014 through September 30, 2015)
Revenues were $71,704,531 for the full year, as compared to $21,191,600 for the prior year, an increase of 238%.
Adjusted EBITDA(1) was $11,818,221 for the full year, as compared to $4,354,683 for the prior year, an increase of 171%.
Key Financial Figures for Audited FY 2013-2015
Audited FY 2015 FY 2014 FY 2013 Revenue $71,704,531 $21,191,600 $3,975,742 Gross Margin $47,042,594 $13,594,711 $2,602,358 Gross Margin% 66% 64% 65% Adjusted EBITDA(1) $11,818,221 $4,354,683 $(1,890,337) Cash $51,592,888 $14,050,436 $3,360,823
Full results have been posted on SEDAR.
“The year-end results, coupled with the first quarter, provides a good perspective of PHM’s tremendous and consistent growth,” said Casey Hoyt, CEO of PHM. “In just over two years, PHM has grown from a company with about $1,000,000 of quarterly revenue to a company with over $40,000,000 of quarterly revenue, all while growing profitability, our balance sheet and EPS along the way. We have plenty of cash on hand, growing cash flow and limited debt. In 2016 we are well positioned to take advantage of our national footprint with a growing sales force and product and service lines.”
Belle news, je viens de vendre 1/3 de ma position acheté à 0.55$ à 0.73$ pour 33% de profit. Je laisse le reste rider.
Ils attendaient la fin du T1 pour avoir de bonnes news financières avant de divulguer le T4.
De toute beauté, on a touché 0.87$
Que pensez vous de PHM a ce prix? (0.43$)
bon point d’entre ou il risque de continuer a descendre?
Valeur comptable tangible par action = 0.17$ (0.16$ si provision de 5% sur les recevables)
BAIIA ajusté selon le MD&A = 7.722M$
Valeur de l’entreprise / BAIIA = 4.88x
Belle croissance des revenus de 36% sur le trimestre précédent, mais cela inclut l’acquisition de Patient Aids. Selon mes estimations, la croissance organique a été d’environ 20% sur le trimestre précédent.
Je n’aime pas les recevables élevés au bilan. Les mauvaises créances ont atteint 4.3% des ventes au Q1, je modéliserais un 5% sur les ventes futures. Même on ajuste le BAIIA, l’évaluation reste intéressante à 5.08x le BAIIA.
Personnellement, je vois beaucoup de résistance vers le haut avec la chute du prix de l’action. Il y a beaucoup d’actions, d’options et de bons de souscription (warrants) en circulation. Finalement, j’ai des doutes sur le management après le fiasco du départ de l’ancien CEO et de la création de leurs fonds d’investissement en santé.
Peut-être que cela pourrait intéresser certain d’entre vous, un vent nouveau pour l’entreprise, Séparation de la compagnie en 2.
En cherchant pour de nouvelles idées d’investissement je suis tombé sur cet article:
En gros PHM de jadis est devenu deux nouvelles entreprises: Viemed Healthcare (VMD) et Protech Home Medical PTQ) et les deux ont un nouveau management depuis environ un an. Depuis ce temps l’action de VMD a plus que doublé et PTQ semble en voie de connaître le même genre de croissance. Les revenus sont en hausse, les marges s’améliorent et la demande pour leurs produits et services devrait augmenter avec le vieillissement de la population. Je trouve le titre intéressant et je vais poursuivre mes recherches, mais je suis curieux de savoir si vous suivez un peu PTQ et ce que vous en penser.
PTI rapport de Beacon https://www.protechhomemedical.com/pdf/PTQ-2019-03-13.pdf
Il y aussi eu cette nouvelle last week https://stockhouse.com/news/press-releases/2019/04/17/protech-announces-execution-of-an-loi-to-acquire-a-profitable-business-in-the
Merci pour les informations. Je n’ai toujours pas de position, mais je continue à surveiller le titre.